Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $81.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective lifted by equities researchers at Jefferies Financial Group from $66.00 to $81.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 52.84% from the company’s current price.

Several other equities analysts have also weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $46.00 target price on shares of Dianthus Therapeutics in a report on Monday, December 22nd. Truist Financial lifted their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright raised their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $66.50.

Dianthus Therapeutics Trading Down 0.7%

NASDAQ DNTH traded down $0.40 on Monday, reaching $53.00. 327,902 shares of the company were exchanged, compared to its average volume of 912,908. The business’s fifty day moving average price is $43.79 and its 200 day moving average price is $35.24. The stock has a market capitalization of $2.29 billion, a P/E ratio of -15.23 and a beta of 1.55. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $57.50.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Equities research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Simrat Randhawa sold 109,031 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $152,560. The trade was a 96.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 216,538 shares of company stock valued at $8,283,175 in the last ninety days. 8.15% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently bought and sold shares of the company. UBS Group AG grew its stake in Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after purchasing an additional 469,547 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after buying an additional 406,254 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $135,000. Palumbo Wealth Management LLC grew its position in shares of Dianthus Therapeutics by 125.1% during the fourth quarter. Palumbo Wealth Management LLC now owns 14,967 shares of the company’s stock worth $617,000 after buying an additional 8,317 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $765,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.